Navigation Links
AMDL, Inc. Retains Strategic Growth International Inc. as its Global Investor Relations Advisor
Date:6/20/2008

NEW YORK, June 20 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), announced today it has retained Strategic Growth International, Inc. ("SGI"), a global investor relations firm, to assist the Company in growing its financial market presence. SGI will assist the Company in establishing a stronger understanding of the investment opportunity AMDL represents while increasing the Company's awareness across global investment communities.

Gary Dreher, CEO of AMDL, commented, "As we continue building AMDL into a world-class pharmaceutical company we feel strong communications is imperative to our success. SGI has a strong reputation with an exceptional team and we're excited to have them as a partner to communicate our corporate story, the great progress we're making with new products and technologies in the U.S., China, and other global markets, and most important, how we intend to meet our stated financial targets of doubling annual sales consecutively over the next 3 years."

SGI Co-Founder Rich Cooper also commented saying, "We believe a strong investment story exists with AMDL and we're excited the company has chosen us to support their IR efforts. Through our combined efforts we will focus on achieving a fair and sustainable market valuation for AMDL while enhancing their reputation with investors, analysts, and the financial media."

Founded in 1989, SGI is headed by Richard E. Cooper and Stanley Altschuler, both long-time and highly-respected Wall Street veterans. Prior to his co-founding SGI, Mr. Cooper was a Managing Director at Salomon Brothers for five of his 14 years at the firm. Mr. Altschuler owned and managed a New York-based brokerage firm.

About AMDL

AMDL, Inc. is a global specialty pharmaceutical company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

AMDL Contact: Investor Relations Contact:

Kristine Szarkowitz Strategic Growth International, Inc.

Director-Investor Relations Richard E. Cooper - rcooper@sgi-ir.com

kszarkowitz@amdl.com Cass Almendral - cass@sgi-ir.com

(206) 310-5323 (212) 838-1444/ http://www.sgi-ir.com


'/>"/>
SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SPO Medical Retains American Capital Ventures for Investor Relations Services
2. Interleukin Genetics Retains Top Life Science Communications Firms
3. Dragon retains leading investor relations firm
4. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
5. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
6. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
7. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. Paul Capital Healthcare Leads Panel on Strategic Financing
10. AHIMA Reacts in Support of NAHITs New Strategic and Operating Framework
11. Official Signing Ceremony for WIBP Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... Madras in India. , Dr. Thomas’ career as an academic and industry ...
(Date:1/21/2017)... ... ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. (New York, USA) announced ... and sales rights for all non-OEM Transonic products in Japan. As partners for more ... Nipro - Transonic JV is a natural next step to advance best practices and ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, today presented ... compound, napabucasin, at the 2017 American Society of Clinical ... Francisco . In a Phase ... agent designed to inhibit cancer stemness pathways by targeting ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
Breaking Biology Technology:
(Date:1/19/2017)... and PUNE, India , January 19, 2017 ... "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - 2022," the global ... a CAGR of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... high-level security for both public and private sectors. ... ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
Breaking Biology News(10 mins):